# InduPro

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/indupro

- Industry: Healthcare
- Headquarters: Seattle, US
- Website: www.induprotx.com
- Total disclosed funding: $102M
- Latest round: Series B (Aug 12, 2026)
- Investors on record: 8

## About

Based in the United States, InduPro, Inc. operates as a biotechnology therapeutics developer. The company provides proximity-guided platforms, bispecific antibody-drug conjugates, T-cell engager programs, and autoimmune and oncology drug candidates. Based in the United States, InduPro, Inc. operates as a biotechnology therapeutics developer. The company provides proximity-guided platforms, bispecific antibody-drug conjugates, T-cell engager programs, and autoimmune and oncology drug candidates. Based in Washington, United States and founded in 2022, InduPro, Inc. provides proximity-based biologic therapeutics for oncology and autoimmune diseases. The company develops therapies by defining and manipulating membrane protein spatial relationships. InduPro, Inc. raised USD 77 million Series B in August 2026 from The Column Group, with participation from other investors MRL Ventures Fund, Emerson Collective, Euclidean Capital, Vida Ventures, Eli Lilly & Company, Sanofi and Solasta Ventures. As of August 2026, the company is founded by K. Christopher Garcia, Scott Lesley, Rob Oslund and Niyi Fadeyi and led by its CEO, Prakash Raman, Ph.D., who joined in April 2024. The company works with biopharmaceutical partners and internal scientific teams to develop proximity-guided therapeutics that target cell surface protein neighborhoods. Its platforms include Membrane Interactomics, MInt, for identifying novel targets and co-target pairings, ARRIS for bringing proteins together using multi-specific antibody technology, and Therapeutic Engineering for protein characterization and optimization. Its pipeline includes IDP-001, a bispecific ADC targeting EGFR and TAPA-E1, plus ADC, T-cell engager, PD1 antagonist, and PD1 agonist programs focused on oncology, immuno-oncology, and autoimmune disease research, with clinical development beginning for IDP-001 in 2026.  The company’s revenue is generated by biotechnology collaborations, licensing arrangements, research funding, and potential therapeutics commercialization. In a normal transaction, pharmaceutical partners fund research or make equity investments to access InduPro, Inc.’s proximity-guided platform, as seen in Sanofi’s preclinical collaboration and Eli Lilly and Company’s global strategic collaboration. Future revenues could also come from milestone payments, option rights, licensing economics, or commercialized drug candidates if programs advance, subject to successful development and approvals. With the recent USD 77 million Series B financing closed in August 2026, the company plans to grow by advancing Phase 1 clinical development and early proof-of-concept data for IDP-001. InduPro, Inc. also plans to advance its broader preclinical pipeline across oncology and autoimmune diseases using its proximity-guided discovery platforms and partnerships.

## Funding rounds

- Series B, Aug 12, 2026, $77M — The Column Group, Sanofi, Eli Lilly & Company, Euclidean Capital, Vida Ventures, MRL Ventures Fund, Solasta Ventures, Emerson Collective
- Series A, Jun 13, 2024, $25M — The Column Group, Emerson Collective, Vida Ventures, Euclidean Capital, MRL Ventures Fund

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B
- Emerson Collective — Series A, Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A, Series B
- Euclidean Capital — Series A, Series B
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A, Series B
- Sanofi — Series B
- Eli Lilly & Company — Series B
- Solasta Ventures (https://capitalatlas.ai/funds/solasta-ventures) — Series B